Transcriptional profiling identifies Id2 function in dendritic cell development.

Christine Hacker; Ralf D Kirsch; Xin-Sheng Ju; Thomas Hieronymus; Tatjana C Gust; Christiane Kuhl; Thorsten Jorgas; Steffen M Kurz; Stefan Rose-John; Yoshifumi Yokota; Martin Zenke

doi:10.1038/ni903

PubMed · 12598895

Transcriptional profiling identifies Id2 function in dendritic cell development.

Christine Hacker·Ralf D Kirsch·Xin-Sheng Ju·Thomas Hieronymus·Tatjana C Gust·Christiane Kuhl·Thorsten Jorgas·Steffen M Kurz·Stefan Rose-John·Yoshifumi Yokota·Martin Zenke

View original source ↗Export metadata ↓

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells with a pivotal role in antigen-specific immune responses. Here, we found that the helix-loop-helix transcription factor Id2 is up-regulated during DC development in vitro and crucial for the development of distinct DC subsets in vivo. Id2-/- mice lack Langerhans cells (LCs), the cutaneous contingent of DCs, and the splenic CD8alpha+ DC subset is markedly reduced. Mice deficient for transforming growth factor (TGF)-beta also lack LCs, and we demonstrate here that, in DCs, TGF-beta induces Id2 expression. We also show that Id2 represses B cell genes in DCs. These findings reveal a TGF-beta-Id2 signaling pathway in DCs and suggest a mechanism by which Id2 affects the lineage choice of B cell and DC progenitors.

Explore related subjects

B-Lymphocytes Cell Differentiation DNA-Binding Proteins Dendritic Cells Gene Expression Profiling Humans Inhibitor of Differentiation Protein 2 Oligonucleotide Array Sequence Analysis Receptors, Granulocyte-Macrophage Colony-Stimulating Factor Receptors, Interleukin-4 Repressor Proteins Transcription Factors Transforming Growth Factor beta Up-Regulation Journal Article Research Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Christine Hacker, Ralf D Kirsch, Xin-Sheng Ju, Thomas Hieronymus, Tatjana C Gust, Christiane Kuhl, Thorsten Jorgas, Steffen M Kurz, Stefan Rose-John, Yoshifumi Yokota, Martin Zenke. 2003-02-24. Transcriptional profiling identifies Id2 function in dendritic cell development.. https://doi.org/10.1038/ni903

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

CD56+ cells induce steroid resistance in B cells exposed to IL-15.

Interleukin-2 can induce steroid resistance in T cells. IL-15 shares biological activities with IL-2, as both cytokines use IL-2Rgamma for signal transduction. We therefore sought to determine whether IL-15 contributes to induction of PBMC corticosteroid resistance. Surprisingly, we found that incubation of unfractionated PBMC with IL-15 for 48 h resulted in the inhibition of glucocorticoid receptor (GCR) nuclear translocation in response to dexamethasone (DEX) treatment in CD19-positive B cells significantly greater than CD19-negative non-B cells (p < 0.01). However, pure B cells incubated with IL-15 responded normally with nuclear translocation of GCR in response to steroids, but failed to translocate GCR when they were grown in the presence of CD19(-) cells. Coculture of B cells with CD3(+) (T cells), CD14(+) (monocytes), or CD56(+) (NK and NKT cells) in the presence of IL-15 revealed that only CD56(+) cells contributed to the steroid insensitivity of B cells. IL-15 stimulation significantly increased production of IL-4 by CD56(+) cells (p < 0.02). Treatment of purified B cells with combination IL-15/IL-4 resulted in abrogation of glucocorticoid receptor nuclear translocation and the inability of DEX to suppress cytokine production by B cells. In the presence of IL-4-neutralizing Ab, when B cells were cocultured with CD56(+) cells and IL-15, the B cells were found to be steroid sensitive, i.e., DEX induced GCR nuclear translocation. This study demonstrates that B cells develop steroid resistance in the presence of CD56(+) cells after IL-15 stimulation. Furthermore, IL-15 and IL-4 have the capacity to induce B cell insensitivity to steroids.

B-Lymphocytes↗

PubMed2004

Effect of novel non-peptidic delta opioid receptor antagonists on human T and B cell activation.

The effects of the antagonist naltrindole (NTI) on cells of the immune system have been largely studied although the mechanisms of action are still unclear. The aim of this study is to evaluate, in vitro, the immunomodulatory activity of four new delta-selective opioid compounds structurally related to naltrindole. The effects at different concentrations of these opioid antagonists on proliferative response were studied on normal human peripheral blood mononuclear cells (PBMC) stimulated with different stimuli: mitogens, the antigen PPD, the anti-CD3 monoclonal antibodies (mAb), the superantigen Staphylococcus aureus Cowan strain 1 (SAC) and alloantigens in the mixed lymphocyte cultures (MLR). The immunomodulatory capacity of these compounds was evaluated by determining the interleukin-2 (IL-2) release in mitogen activated PBMC. The present study shows that all the new delta opioid antagonists at 10(-5) M concentration are immunosuppressive. The inhibitory action is also evident at lower concentrations when anti-CD3 mAb and SAC were used as stimulators. In addition, the production of IL-2 was inhibited by the opioid treatment, but this might not be the only mechanism of action.

B-Lymphocytes↗

PubMed2004

Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.

Epstein-Barr virus (EBV)-encoded nuclear antigen (EBNA)1 is thought to escape cytotoxic T lymphocyte (CTL) recognition through either self-inhibition of synthesis or by blockade of proteasomal degradation by the glycine-alanine repeat (GAr) domain. Here we show that EBNA1 has a remarkably varied cell type-dependent stability. However, these different degradation rates do not correspond to the level of major histocompatibility complex class I-restricted presentation of EBNA1 epitopes. In spite of the highly stable expression of EBNA1 in B cells, CTL epitopes derived from this protein are efficiently processed and presented to CD8+ T cells. Furthermore, we show that EBV-infected B cells can readily activate EBNA1-specific memory T cell responses from healthy virus carriers. Functional assays revealed that processing of these EBNA1 epitopes is proteasome and transporter associated with antigen processing dependent. We also show that the endogenous presentation of these epitopes is dependent on the newly synthesized protein rather than the long-lived stable EBNA1. Based on these observations, we propose that defective ribosomal products, not the full-length antigen, are the primary source of endogenously processed CD8+ T cell epitopes from EBNA1.

B-Lymphocytes↗